Skip to main content
. 2014 Jan 30;1(1):57–68. doi: 10.18632/oncoscience.9

Figure 3. Array CGH analysis of mutant clones obtained from imatinib and ponatinib experiments.

Figure 3

Potential MS-5 effects were analyzed in (1) two imatinib-resistant UT-7-11 clones harboring the E255K mutation compared with non-mutagenized UT-7-11 control and in (2) two ponatinib-resistant UT-7-315 clones harboring the T315I mutation alone compared with non-mutagenized UT-7-315 control. The total number of variations (losses and gains) is indicated (A) along with variation size (B).